Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

TOKAI PHARMACEUTICALS INC

Delayed Nasdaq  -  03:58:04 2017-05-12 pm EDT
6.130 USD   -3.92%
01/09Eledon Pharmaceuticals, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
01/09Eledon Pharmaceuticals Provides Business and Pipeline Updates
GL
01/09EGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies
AQ
SummaryChartsNewsRatingsCalendarCompanyFunds 
Business Summary
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis (ALS). Its lead compound in development is AT-1501, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand (CD40L, also called CD154). AT-1501 is engineered to improve both safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. Blocking CD40L inhibits both CD40 and CD11 costimulatory signaling pathways with the potential for better efficacy. It is focused on developing AT-1501 in up to four indications: ALS, prevention of kidney allograft rejection, prevention of islet cell allograft rejection, and IgA Nephropathy (IgAN). It has completed a Phase Ia/Ib single ascending dose trial in volunteers and people with amyotrophic lateral sclerosis (ALS).
Managers
Name Title Age Since
David-Alexandre C. Gros, Dr. Chief Executive Officer & Director 50 2020
Steven N. Perrin, Dr. President, Director & Chief Scientific Officer 57 2020
Paul Little Chief Financial & Accounting Officer 58 2021
Jeffrey D. Bornstein, Dr. Chief Medical Officer - 2021
John Herberger Vice President-Technical Operations - 2022
Bryan E. Smith Secretary, Compliance Officer & General Counsel 43 2021
David Hovland, Dr. Chief Regulatory Officer - 2021
Members of the board
Name Title Age Since
Keith A. Katkin Chairman 50 2017
Gary Lyons Independent Director 70 2017
John S. McBride Independent Director 70 2017
Walter C. Ogier Independent Director 65 2020
June Lee Independent Director 56 2020
Jan L. Hillson, Dr. Independent Director - 2021
David-Alexandre C. Gros, Dr. Chief Executive Officer & Director 50 2020
Steven N. Perrin, Dr. President, Director & Chief Scientific Officer 57 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 13,756,788 12,411,526 90.2% 0 0.0% 90.2%
Stock B 0 6,204 0 0.0% 0 0.0%
Stock C 0 117,970 0 0.0% 0 0.0%
Shareholders
NameEquities%
BVF Partners LP 2,326,710 16.9%
Logos Global Management LP 1,339,793 9.74%
Cormorant Asset Management LP 1,223,500 8.89%
Ecor1 Capital LLC 1,115,721 8.11%
The Vanguard Group, Inc. 674,206 4.90%
Woodline Partners LP 516,675 3.76%
Fidelity Management & Research Co. LLC 504,371 3.67%
Adage Capital Management LP 409,759 2.98%
Medical Strategy GmbH 375,598 2.73%
Point72 Asset Management LP 375,000 2.73%
Company contact information
Eledon Pharmaceuticals, Inc.
19900 MacArthur Boulevard
Suite 550
Irvine, CA 92612

Phone : +1.949.238.8090
Web : http://eledon.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Tokai Pharmaceuticals Inc